View Clause Headings                                                                                                                                               HelpHelp
DOCUMENT TITLE:  AMENDED AND RESTATED STRATEGIC COLLABORATION AND LICENSE AGREEMENT .
ACTIONS: Here are the clause headings in the document. To view the clause, click the clause heading.To view the full document, click the "View Document" button.

View Document Back
Clause Heading
ARTICLE 2 - EQUITY INVESTMENT
ARTICLE 3 - MANUFACTURING SERVICES RELATIONSHIP
4.1 - Research Management Committee.
4.2 - Single Stranded RNAi Collaboration.
(a) - Research Plan.
(b) - Research Staffing.
(c) - Research Funding.
(d) - Materials Transfer.
(a) - Enabled Targets.
(b) - Designating Enabled Targets.
(c) - Determining First Turn.
(d) - Removing Enabled Targets.
(g) - Review Designating Process.
ARTICLE 5 - LICENSES GRANTED BY ISIS TO ALNYLAM; AND
(e) - Isis Protected Targets.
(f) - Confidentiality.
5.1 - License Grants.
5.2 - License Exclusivity, Territory and Sublicenses.
5.3 - Limitations on Licenses.
5.4 - Alnylam Covenant Regarding Sublicensing of Isis Patent Rights.
5.5 - Isis Covenant to Alnylam Regarding Co-Exclusivity for Single Stranded RNAi Products.
ARTICLE 6 - LICENSES GRANTED BY ALNYLAM TO ISIS; AND
6.1 - License Grants.
6.2 - License Option.
6.3 - Sublicenses.
(a) - Reserved DS-Target Slots.
(b) - Initial Designations.
(c) - Removing/Adding DS-Targets.
(d) - New Target Request.
(e) - New Target Rejection/Approval.
(g) - Diligence on Rejected Targets.
(h) - Diligence Obligations in Third Party Contractual Obligations.
(i) - Confidentiality.
6.5 - Limitations on Licenses.
6.6 - Alnylam Covenant to Isis Regarding Co-Exclusivity for Single Stranded RNAi Products.
7.1 - License Fees.
7.2 - Royalties.
(a) - Single Stranded Research Milestones.
(b) - Single Stranded Development Milestones.
(c) - Double Stranded Development Milestones.
(d) - MicroRNA Milestone.
7.7 - Revenue Sharing for Research Program Patents.
ARTICLE 8 - LICENSE FEES, SUBLICENSE REVENUE AND
7.4 - Sublicensing Revenue on Naked Sublicenses and Single Stranded Sublicenses.
7.5 - Technology Access Fees from Bona Fide Collaborations.
7.6 - Allocation of Sublicense Income and Technology Access Fees.
8.1 - Option Fee.
8.2 - Royalties.
8.3 - Development Milestones.
8.4 - Sublicense Income on Single Stranded RNAi Sublicenses.
8.5 - Revenue Sharing for Research Program Patents.
9.1 - Payments.
9.2 - Late Payments; Collections.
9.3 - Audit Rights.
9.4 - Taxes.
10.1 - Right of First Negotiation.
10.2 - Preferred Licensee.
11.1 - Ownership of Inventions.
11.4 - Costs and Expenses.
11.5 - Enforcement.
11.7 - Third Party Patents.
11.2 - Filing and Prosecution of Isis and Alnylam Patent Rights.
11.3 - Filing and Prosecution of Jointly Owned Patents.
11.8 - Future Licenses.
12.1 - Nondisclosure Obligation.
13.3 - Notification of Claims; Conditions to Indemnification Obligations.
12.2 - Permitted Disclosures.
12.3 - Announcements; Publicity.
13.1 - Indemnification by Alnylam.
13.2 - Indemnification by Isis.
14.1 - Term and Termination of Agreement.
14.2 - Termination upon Material Breach.
14.3 - Termination upon Bankruptcy; Rights in Bankruptcy.
14.4 - Alnylams Limited Right to Terminate the Research Program.
14.5 - Accrued Rights and Surviving Obligations.
15.1 - Representations and Warranties of the Parties.
15.2 - Disclaimers.
16.1 - Notice.
17.1 - Relationship of the Parties.
17.2 - Successors and Assigns.
17.3 - Entire Agreement; Amendments.
17.4 - Force Majeure.
17.5 - Applicable Law.
17.6 - Dispute Resolution.
17.7 - No Consequential Damages.
17.8 - Captions.
17.9 - Waiver.
17.10 - Compliance with Law.
17.11 - Severability.
17.12 - Waiver of Rule of Construction.
17.13 - Counterparts.
17.14 - Performance by Affiliates.
17.15 - No Implied License.
1 - Merck
2 - Gilead Sciences, Inc.
4 - Tullis Patents.
5 - Amgen, GSK, Chiron and Pfizer.
6 - Integrated DNA Technologies, Inc.
7 - TriLink Biotechnologies, Inc.
8 - Government Rights
2.4 - Sublicenses
4.1 - Activity Requirements
4.2 - Development Reports
4.4 - Liability for SUBLICENSEES
4.5 - Effect of Failure
5.2 - Running Royalties
(a) - Third Party Licenses
(b) - PATENT RIGHTS Coverage
5.4 - Reports
5.6 - Bookkeeping and Auditing
5.7 - No Refund
6.3 - Infringement
ARTICLE 8 - CONFIDENTIALITY
10.2 - Non-Use of OWNERS Names
11.5 - Attack on PATENT RIGHTS
11.8 - Effect of Termination
7.1 - Quarterly Earned Royalty Payment and Report.
7.2 - Termination Report.
7.3 - Accounting.
8.2 - Negation of Warranties.
8.3 - No warranties.
8.4 - Specific Exclusion.
9.1 - Indemnification.
9.2 - No Liability.
9.3 - Workers Compensation.
9.4 - Insurance.
12.1 - Infringement Action.
13.1 - Permitted Sublicensing for Licensed Co-Exclusive Field of Use.
13.2 - Required Sublicensing for Licensed Co-Exclusive Field of Use.
13.3 - Sublicense Requirements.
13.5 - Copy of Sublicenses.
13.6 - Sharing of Sublicensing Income.
13.7 - Royalty-free Sublicenses.
3.2 - Co-Exclusivity.
3.4 - Exclusivity.
6.3 - Earned Royalty.
6.4 - Creditable Payments.
6.5 - Milestone Payments.
6.6 - Obligation to Pay Royalties.
13.4 - Sublicenses Revert to Stanford.
1 - INTELLECTUAL PROPERTY COVERING:
3 - GEN-PROBE AND NIH.
7 - MERCK NUCLEOSIDE
8 - CARNEGIE INSTITUTION OF WASHINGTON.
9 - GARCHING INNOVATION GMBH.